NovaBay Pharmaceuticals, Inc. (NBY) Receives $6.00 Consensus Price Target from Analysts
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.00.
NBY has been the topic of a number of research analyst reports. HC Wainwright set a $4.00 target price on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 6th. Zacks Investment Research lowered shares of NovaBay Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 17th.
NYSEAMERICAN:NBY traded down $0.15 during midday trading on Friday, reaching $1.91. The stock had a trading volume of 15,746 shares, compared to its average volume of 12,836. NovaBay Pharmaceuticals has a 1-year low of $1.25 and a 1-year high of $4.80.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Recommended Story: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.